Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
China-based Innovent Biologics, Inc. (HKG: 1801) and its partner Eli Lilly & Co. (NYSE: LLY)...
Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...
US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...
Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...
China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...